



ASX ANNOUNCEMENT

Victorian Government Intent to Support Lumos Local Manufacturing & Innovation Hub

- *In-principle offer subject to formal legal agreements and TGA approval of Lumos CoviDx™ test*
- *Victorian Government to provide support for investment in \$17.2M Diagnostics Manufacturing Facility and Innovation Hub*
- *Initial focus on Covid-19 Rapid Antigen Test (RAT)¹ production with priority supply to Victorian Government*
- *Establishment of a future Innovation Hub to support Australian health technology commercialisation*

Melbourne, VIC. (02 February 2022) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, advises that today the Victorian State Government has announced an intended package of support for and collaboration with Lumos to establish a manufacturing capability in Rapid Antigen Tests (RAT) in Victoria. Subject to meeting a number of requirements, including Lumos successfully securing approval from the Australian Therapeutic Goods Administration (TGA) for its COVID-19 RAT test, CoviDx™, the facility could be producing RATs in early Q2 CY2022.

The need to establish a local capability for manufacturing rapid diagnostics has been highlighted by the critical shortages of COVID-19 RAT tests experienced across Australia in recent months. In response to this, Lumos Diagnostics and the Victorian Government have been working towards a plan to establish local production of Lumos’ COVID-19 RAT test CoviDx™ by early Q2 CY2022. Once established, the aim will be to increase the facility’s capabilities by building out production lines, expanding automation and introducing new products.

For this potential project to proceed to the next step of finalizing a legal agreement, Lumos needs to secure approval from the TGA for over-the-counter (OTC) use of its CoviDx™ RAT. The Company has an application with the TGA with the aim of securing the necessary approvals to market CoviDx™ in Australia.

¹ CoviDx™ detects the SARS-CoV-2 virus that causes the disease called COVID-19



If it were to proceed, the Victorian Government has indicated it will co-invest with Lumos to progressively establish a \$17.2 million Diagnostics Manufacturing Facility and Innovation Hub in Victoria and be an early purchaser of the CoviDx™ RATs. The production and assembly facility will be set up within an existing space provided to Lumos' via founding shareholder, Planet Innovation. The investment aims to produce 1 million tests initially and up to 50 million rapid tests per year by introducing greater automation and expanding production lines subject to market demand. While the current focus on RATs is for the management of COVID-19, they are increasingly being used for influenza, infectious diseases, reproductive health and chronic disease management.

“Lumos Diagnostics is proud to collaborate with the Victorian Government to manufacture and deliver critical, rapid diagnostic tests. Lumos will leverage its existing partnerships and global experience that has seen it create critical infrastructure and world-class technology in North America, to support the establishment of a Victorian manufacturing and innovation hub for rapid diagnostics,” said Sam Lanyon, Executive Chair of Lumos Diagnostics. “We are thrilled that as an organisation that was founded in Victoria, we can support the creation of local jobs whilst future proofing Victoria’s needs for rapid testing.”

For more information, refer to the announcement by the Victorian Government which has been posted on the following webpage: <https://www.premier.vic.gov.au/media-centre>.

This announcement is authorised for release to the market by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and



speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Jennifer Christiansen – Global
VP, Corporate Marketing and Communications, Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598